TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tvardi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.97−0.04 (-3.96%)
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$5.6100 (−85.26%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $9.10M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.09
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$26.06M
- EPS, diluted
- -$3.26
- Book value per share
- $0.89
- Diluted shares
- 9M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$27.21M
Net income
-$26.06M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months